García-Fortes, MaríaHernández-Boluda, Juan CÁlvarez-Larrán, AlbertoRaya, José MAngona, AnnaEstrada, NataliaFox, LauraCuevas, BeatrizGarcía-Hernández, María CGómez-Casares, María TeresaFerrer-Marín, FranciscaSaavedra, SilvanaCervantes, FranciscoGarcía-Delgado, ReginaOn Behalf Of The Grupo Español de Enfermedades Mieloproliferativas Filadelfia Negativas Gemfin,2023-05-032023-05-032022-05-092072-6694http://hdl.handle.net/10668/20891The comorbidity burden is an important risk factor for overall survival (OS) in several hematological malignancies. This observational prospective study was conducted to evaluate the impact of individual comorbidities on survival in a multicenter series of 668 patients with primary myelofibrosis (PMF) or MF secondary to polycythemia vera (PPV-MF) or essential thrombocythemia (PET-MF). Hypertension (hazard ratio (HR) = 4.96, penAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/comorbiditiesmyelofibrosisprognosissurvivalresearch article35565461open access10.3390/cancers14092331PMC9104306https://www.mdpi.com/2072-6694/14/9/2331/pdf?version=1652069834https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9104306/pdf